Nicholas Denomme, Ciria C Hernandez, Hailey A Bock, Rachel F Ohana, Shreeya Bakshi, Alexander M Sherwood, John D McCorvy, Paul F Daley, Wyeth B Callaway, Jacob M Hull, Andrew Alt, Lori L Isom, Nicholas V Cozzi
Bipolar disorder impacts millions of patients in the United States but the mechanistic understanding of its pathophysiology and therapeutics is incomplete. Atypical antipsychotic serotonin2A (5-HT2A ) receptor antagonists, such as quetiapine and olanzapine, and mood-stabilizing voltage-gated sodium channel (VGSC) blockers, such as lamotrigine, carbamazepine, and valproate, show therapeutic synergy and are often prescribed in combination for the treatment of bipolar disorder. Combination therapy is a complex task for clinicians and patients, often resulting in unexpected difficulties with dosing, drug tolerances, and decreased patient compliance...
May 31, 2024: Molecular Pharmacology